Close
The page header's logo
Help
Login
Staff Login
Register
FR
0
Selected 
Invert selection
Deselect all
Deselect all
 Add to Cart
 Click here to refresh results
 Click here to refresh results
Go to Login page
 Hide details
doctype icon
Conceptually similar
Pfizer: COVID pill cut hospital, death risk by 90%
play button
CP140171171 | Pfizer: COVID pill cut hospital, death risk by 90% 
Health Canada approves Pfizer COVID-19 treatment
play button
CP148756971 | Health Canada approves Pfizer COVID-19 treatment 
Fauci: US to spend $3.2B for COVID antiviral pills
play button
CP125273000 | Fauci: US to spend $3.2B for COVID antiviral pills 
FDA panel narrowly backs COVID-19 pill from Merck
play button
CP143124202 | FDA panel narrowly backs COVID-19 pill from Merck 
Why Pfizer needs time to make COVID-19 treatment
play button
CP151892840 | Why Pfizer needs time to make COVID-19 treatment 
FDA panel backs Pfizer's COVID-19 vaccine for kids
play button
CP138908121 | FDA panel backs Pfizer's COVID-19 vaccine for kids 
FDA panel reviews Pfizer's COVID vaccine for kids
play button
CP138845871 | FDA panel reviews Pfizer's COVID vaccine for kids 
CDC panel debates Pfizer's COVID vaccine for kids
play button
CP139796854 | CDC panel debates Pfizer's COVID vaccine for kids 
FDA gives full approval to Pfizer COVID-19 vaccine
play button
CP130270171 | FDA gives full approval to Pfizer COVID-19 vaccine 
UK to begin Pfizer COVID-19 vaccine emergency use
play button
CP112461971 | UK to begin Pfizer COVID-19 vaccine emergency use 
Action button

Pfizer COVID-19 antiviral pills arrive in SKorea

South Korea on Thursday received its first supply of Pfizer's antiviral COVID-19 pills to treat patients with mild or moderate symptoms. (Jan. 13) 
Actions
 Add to collection
 Add to cart
Information
Source name: 
The Associated Press
Unique identifier: CP148225771 
Legacy Identifier: 802d800b83d64c658071185f156a5d97 
Type: Video 
Duration: 1m7s 
Dimensions: 1920px × 1080px     82.03 MB 
Usage rights: Digital platform use only. Broadcast rights and editing of content prohibited. 
Create Date: 1/13/2022 6:39:54 AM 
Display aspect ratio: 16:9